RRIF Rainforest Resources Inc (CE)

BioChem Solutions Inc. (Pink Sheets:BCHS) announced it has now committed to proceeding with the Phase III trials for Arthromir and Alphamir drugs that have been developed and derived from trioxolane as stated in a prior news release. This research is being conducted under FDA protocol guidelines at the Kenya Medical Institute (KEMRI). This research is piggy-backed onto the favorable results seen in the Phase II trials conducted in 2004. In these trials, two groups of 200 people will be included within the test and control groups with the testing to be completed over a three-month period and then a subsequent two-month evaluation period included in the estimated cost of $589,000. Testing will be done for the treatment of acute respiratory infections, rheumatoid arthritis and HIV. As the results are compiled they will be released and the next stages in the commercial development of the drugs announced. This Press Release may contain certain forward-looking statements that are based on management�s expectations, estimates, projections and assumptions. Words such as �expects,� �anticipates,� �plans,� �believes,� �scheduled,� �estimates,� and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, and stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors beyond the control of management. All forward-looking statements speak only as of the date of this release, or, in the case of any documents incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company�s behalf are qualified by the cautionary statements in this section. The company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.